|
TCIRG1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
7.518200E-02 |
| Normal-vs-Stage3 |
1.63469238145808E-12 |
| Normal-vs-Stage4 |
7.43849426498855E-15 |
| Stage1-vs-Stage2 |
5.71830000000162E-05 |
| Stage1-vs-Stage3 |
1.185000E-01 |
| Stage1-vs-Stage4 |
7.040000E-03 |
| Stage2-vs-Stage3 |
2.13039999999998E-05 |
| Stage2-vs-Stage4 |
2.53680000006362E-07 |
| Stage3-vs-Stage4 |
2.184000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.015530E-04 |
| Normal-vs-Asian |
2.28306262783917E-12 |
| Caucasian-vs-AfricanAmerican |
7.363000E-01 |
| Caucasian-vs-Asian |
1.288850E-01 |
| AfricanAmerican-vs-Asian |
4.920000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66877622831407E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.741000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
5.21804821573824E-15 |
| Normal-vs-Age(61-80Yrs) |
1.59559999657333E-08 |
| Normal-vs-Age(81-100Yrs) |
2.616300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.041000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.451810E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.744000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.952400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.311200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.311000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.412400E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
6.479600E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.43399958574264E-10 |
| Tall-VS-Other |
3.003200E-01 |
| Tall-VS-Normal |
3.43220007970046E-10 |
| Follicular-VS-Other |
8.981000E-03 |
| Follicular-VS-Normal |
2.635200E-01 |
| Other-VS-Normal |
1.961720E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.50963702544504E-12 |
| Normal-vs-N1 |
8.97748542172394E-12 |
| N0-vs-N1 |
1.376110E-02 |
|
|
